Welcome to our dedicated page for Davita news (Ticker: DVA), a resource for investors and traders seeking the latest updates and insights on Davita stock.
DaVita Inc. (NYSE: DVA) is a comprehensive kidney care provider whose news flow reflects its clinical, operational and financial activities in the kidney dialysis centers industry. Company press releases and updates highlight its focus on transforming care delivery for patients with kidney disease, its large global network of outpatient dialysis centers and its role in integrated kidney care and value-based care models.
News about DaVita often covers quarterly financial and operating results, where the company reports consolidated revenues, operating income, cash flow and key U.S. dialysis metrics such as treatment volumes, revenue per treatment and patient care costs per treatment. These releases may also discuss share repurchases, debt transactions, credit facility amendments and guidance ranges for adjusted operating income, adjusted diluted net income per share and free cash flow.
Investors and observers can also find updates on clinical research and innovation. DaVita publishes information about studies presented at events like the American Society of Nephrology’s Kidney Week, including research on GLP-1 receptor agonist use in end-stage kidney disease, home dialysis outcomes, transplant access and end-of-life care. Additional news may describe initiatives such as the MODEL and MEMOIRS evaluations of medium cut-off dialyzers and efforts to better understand middle-molecule clearance.
Other DaVita news items include leadership appointments, participation in investor conferences and statements on government programs such as the Kidney Care Choices (KCC) Model. These communications provide insight into the company’s strategy, governance, integrated kidney care footprint and engagement with value-based care initiatives. For ongoing context on DVA, readers can use this news feed to follow developments in DaVita’s kidney care operations, research programs and capital allocation decisions over time.
DaVita Inc. (NYSE: DVA) announced its quarterly conference call to discuss fourth quarter results scheduled for February 10, 2022, at 5:00 p.m. Eastern Time. Results will be released after market close on the same day. The call will be webcast and accessible via DaVita's investor relations website. DaVita, a leading kidney care provider, serves 203,000 patients at 2,822 outpatient dialysis centers in the U.S. and operates in ten countries worldwide. The company focuses on improving healthcare delivery and clinical quality.
On January 19, 2022, DaVita Integrated Kidney Care launched 11 value-based care programs aimed at supporting approximately 25,000 kidney patients across the U.S. These initiatives align with the government's new Kidney Care Choices (KCC) model, which commenced on January 1, 2022, and spans five years. The program encourages proactive management of chronic kidney disease (CKD) to reduce the need for emergency dialysis, ultimately improving patient outcomes and reducing costs. DaVita IKC aims to double patient participation in integrated kidney care within the first performance year.
On January 18, 2022, DaVita announced its acquisition of MedSleuth, a software company focused on improving kidney and liver transplantation processes. This acquisition enhances DaVita's commitment to innovation in transplant care, aiming to streamline access and improve patient outcomes. MedSleuth’s BREEZE™ software aids in candidate evaluation and increases living donation rates, while MATCHGRID™ improves donor-recipient matching. With this purchase, DaVita aims to break down barriers in kidney care, enhancing health equity and patient experiences in transplantation.
DaVita celebrated its teammates for their outstanding contributions in 2021, notably improving care for kidney patients. CEO Javier Rodriguez highlighted the team's resilience amid challenges, focusing on enhancing kidney care services. Key achievements include administering approximately 217,000 COVID-19 vaccines, achieving high international vaccination rates, and providing at-home dialysis for over 30,000 patients. Additionally, more than 7,500 patients received kidney transplants, reflecting a 3% increase from the previous year. The company is committed to innovation and expanding its integrated care model to further serve communities worldwide.
Summary not available.
DaVita Integrated Kidney Care (IKC) has appointed Dr. David Roer as its new chief medical officer, leading a team of experienced nephrologists to enhance care delivery. The team aims to improve patient care for chronic kidney disease and increase access to home dialysis and kidney transplantation. DaVita IKC currently manages over 30,000 patients and anticipates more than doubling its patient population in 2022 due to new Medicare payment models. This initiative aligns with DaVita's goal of advancing health equity in kidney care.
DaVita Inc has achieved a significant milestone by becoming the first kidney care provider to operate entirely on renewable energy for its North American facilities. This initiative, completed in partnership with Longroad Energy, involved constructing a wind farm and a solar farm in Texas. The company now aims for 100% renewable energy globally by 2025 and has already reduced carbon emissions per dialysis treatment by 19%. Other sustainability efforts include installing energy-efficient systems in 1,200 centers and diverting over 6 million pounds of waste from landfills.
DaVita's 15th annual Tour DaVita event successfully raised nearly $1 million for Bridge of Life, a nonprofit dedicated to improving global healthcare. The event, held virtually from October 1–3, saw around 3,400 participants logging over 26,000 miles to raise awareness for kidney disease. Bridge of Life aims to provide healthcare services in underserved areas, especially crucial during the COVID-19 pandemic. Sponsors included AmerisourceBergen and Wells Fargo, underscoring community support for healthcare initiatives.
On November 29, 2021, DaVita Clinical Research published a study highlighting the effectiveness of mRNA COVID-19 vaccines in dialysis patients. The study found that vaccinated patients had a 78% and 73% efficacy against COVID-19 infection from Pfizer/BioNTech and Moderna vaccines, respectively. Vaccinated individuals were also less likely to experience hospitalization or death following breakthrough infections. This research is significant as it addresses a vulnerable group previously underrepresented in vaccine trials, providing reassurance regarding vaccination's protective benefits for over 500,000 Americans with end-stage kidney disease.
DaVita Clinical Research (DCR) will present eight research abstracts at the ASN Kidney Week 2021, taking place from Nov. 4-7. The event will host over 13,000 kidney care professionals discussing advancements in nephrology. DCR's studies will focus on COVID-19 prevention and improving clinical outcomes, including the effectiveness of mRNA vaccines in dialysis patients. Notable abstracts cover predictive algorithms for hospitalizations and safety of treatments in dialysis centers. DCR aims to enhance collaborative efforts in kidney disease management and clinical research.